SG11201911841PA - Topical formulations comprising montelukast and combinations with mussel adhesive proteins - Google Patents
Topical formulations comprising montelukast and combinations with mussel adhesive proteinsInfo
- Publication number
- SG11201911841PA SG11201911841PA SG11201911841PA SG11201911841PA SG11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA
- Authority
- SG
- Singapore
- Prior art keywords
- montelukast
- combinations
- topical formulations
- mussel adhesive
- adhesive proteins
- Prior art date
Links
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
- 229960005127 montelukast Drugs 0.000 title 1
- 108010004563 mussel adhesive protein Proteins 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017091819 | 2017-07-05 | ||
| CN2018087058 | 2018-05-16 | ||
| PCT/CN2018/094441 WO2019007356A1 (en) | 2017-07-05 | 2018-07-04 | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201911841PA true SG11201911841PA (en) | 2020-01-30 |
Family
ID=64949737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201911841PA SG11201911841PA (en) | 2017-07-05 | 2018-07-04 | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11672792B2 (en) |
| EP (1) | EP3648767A4 (en) |
| JP (1) | JP7288404B2 (en) |
| KR (1) | KR102785243B1 (en) |
| CN (3) | CN110312513B (en) |
| AU (1) | AU2018295944B2 (en) |
| CA (1) | CA3068818A1 (en) |
| MA (1) | MA52924A (en) |
| MX (1) | MX2020000029A (en) |
| MY (1) | MY201703A (en) |
| SG (1) | SG11201911841PA (en) |
| TW (1) | TWI874298B (en) |
| WO (1) | WO2019007356A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS INCLUDING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS |
| SI3678705T1 (en) | 2018-09-14 | 2023-10-30 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | Conjugates of montelukast and peptides |
| MA54707A (en) * | 2019-01-10 | 2021-11-17 | Jiangyin Mucocare Pharmaceutical Co Ltd | NEW FORMULATIONS CONTAINING LEUCOTRIENE RECEPTOR ANTAGONISTS |
| MX2022003057A (en) * | 2019-09-14 | 2022-06-16 | Jiangyin Usun Pharmaceutical Co Ltd | New peptides. |
| CN114929259A (en) * | 2019-12-02 | 2022-08-19 | 艾缇亚(上海)制药有限公司 | Novel multifunctional oligopeptides |
| CN114929283A (en) * | 2019-12-02 | 2022-08-19 | 艾缇亚(上海)制药有限公司 | Novel conjugates of peptides and polysaccharides |
| BR112022015199A2 (en) | 2020-02-03 | 2022-10-11 | Taro Pharma Ind | TOPICAL FORMULATIONS OF MONTELUKAST |
| US12233055B2 (en) | 2020-02-03 | 2025-02-25 | Taro Pharmaceutical Industries Ltd. | Topical Montelukast formulations |
| EP4228641A1 (en) | 2020-10-13 | 2023-08-23 | Diomed Developments Limited | Gel formulations comprising montelukast |
| CN114588267A (en) * | 2020-12-04 | 2022-06-07 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition containing amide local anesthetic |
| US20240165247A1 (en) * | 2021-03-17 | 2024-05-23 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptide conjugates |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| TW202337464A (en) * | 2021-08-06 | 2023-10-01 | 大陸商安利提沙(上海)製藥有限公司 | New treatment of immunodeficiency disorder |
| CN116421547A (en) * | 2023-03-09 | 2023-07-14 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Preparation of a montelukast sodium cream for external use and its application in inflammatory skin diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2213989C (en) * | 1995-12-28 | 2007-05-29 | Yoshitomi Pharmaceutical Industries Ltd. | External preparation for topical administration |
| US20030207932A1 (en) | 2002-05-03 | 2003-11-06 | Morris Mann | Compositions that prevent post-traumatic hyperpigmentation and methods related thereto |
| ATE529125T1 (en) * | 2003-08-07 | 2011-11-15 | Healor Ltd | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ACCELERATING WOUND HEALING |
| US6987170B1 (en) * | 2004-08-09 | 2006-01-17 | Battelle Energy Alliance, Llc | Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis |
| WO2007126865A2 (en) * | 2006-03-30 | 2007-11-08 | Patrin Pharma | Leukotriene antagonists via nasal drug delivery |
| CN1961867A (en) | 2006-11-16 | 2007-05-16 | 徐英权 | Granule formulation of montelukast sodium |
| WO2008106081A1 (en) * | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation |
| WO2008105803A1 (en) | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and uses thereof |
| WO2009137555A1 (en) | 2008-05-06 | 2009-11-12 | Schlesinger S Larry | Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof |
| CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
| GB0915319D0 (en) | 2009-09-03 | 2009-10-07 | Sharma Anant | Combination medicament |
| CN101773503A (en) | 2010-01-12 | 2010-07-14 | 北京华禧联合科技发展有限公司 | Leukotriene antagonist and antihistaminics composition |
| CA2802853C (en) | 2010-06-16 | 2016-07-26 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| CN102895661A (en) * | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | Application of medicine targeting CysLT1 in preparing medicines for preventing or treating autoimmune diseases |
| JP6200432B2 (en) | 2011-12-26 | 2017-09-20 | エスケー ケミカルズ カンパニー リミテッド | Film for oral administration containing montelukast or a pharmaceutically acceptable salt thereof |
| CN103239450B (en) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | Rapidly-dissolving and stabile montelukast oral solid preparation and preparation method thereof |
| EP3308835B1 (en) * | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| CN103655497B (en) | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | A kind of Montelukast Sodium oral disnitegration tablet and preparation method thereof |
| WO2016021599A1 (en) * | 2014-08-04 | 2016-02-11 | 日東電工株式会社 | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition |
| CN105769825A (en) | 2014-12-24 | 2016-07-20 | 广州朗圣药业有限公司 | Oral film and preparation method of montelukast sodium |
| CN105878215A (en) | 2014-12-31 | 2016-08-24 | 天津康鸿医药科技发展有限公司 | Stable montelukast oral rapidly disintegrating film as well as preparation method and application thereof |
| KR101892340B1 (en) * | 2015-03-13 | 2018-08-27 | 경희대학교 산학협력단 | A method to improve montelukast's bio-availability |
| CN104784157B (en) | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | A kind of montelukast oral membrane agent of stabilization |
| WO2017011983A1 (en) * | 2015-07-20 | 2017-01-26 | 江阴市本特塞缪森生命科学研究院有限公司 | Uses of mussel adhesive protein in protection of skin and accessory organs of skin |
| BR112018000953A2 (en) | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | Application of Mussel Mucin Products and Their Inhibition of Skin Inflammation |
| WO2017147067A1 (en) * | 2016-02-22 | 2017-08-31 | Board Of Regents, The University Of Texas System | Antimicrobial compositions and uses thereof |
| US10548837B1 (en) | 2016-05-04 | 2020-02-04 | Taro Pharmaceutical Industries Ltd. | Topical montelukast for treatment of atopic dermatitis |
| EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS INCLUDING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS |
| JP7742226B2 (en) * | 2018-05-28 | 2025-09-19 | ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド | New drug use |
| SI3678705T1 (en) * | 2018-09-14 | 2023-10-30 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | Conjugates of montelukast and peptides |
| MA54707A (en) * | 2019-01-10 | 2021-11-17 | Jiangyin Mucocare Pharmaceutical Co Ltd | NEW FORMULATIONS CONTAINING LEUCOTRIENE RECEPTOR ANTAGONISTS |
-
2018
- 2018-07-04 EP EP18827979.8A patent/EP3648767A4/en active Pending
- 2018-07-04 CN CN201880002883.6A patent/CN110312513B/en active Active
- 2018-07-04 AU AU2018295944A patent/AU2018295944B2/en active Active
- 2018-07-04 CA CA3068818A patent/CA3068818A1/en active Pending
- 2018-07-04 SG SG11201911841PA patent/SG11201911841PA/en unknown
- 2018-07-04 MX MX2020000029A patent/MX2020000029A/en unknown
- 2018-07-04 KR KR1020207003363A patent/KR102785243B1/en active Active
- 2018-07-04 JP JP2019572791A patent/JP7288404B2/en active Active
- 2018-07-04 CN CN202210843681.2A patent/CN115300508A/en active Pending
- 2018-07-04 MA MA052924A patent/MA52924A/en unknown
- 2018-07-04 US US16/628,170 patent/US11672792B2/en active Active
- 2018-07-04 MY MYPI2020000043A patent/MY201703A/en unknown
- 2018-07-04 CN CN202110903665.3A patent/CN113491696A/en active Pending
- 2018-07-04 WO PCT/CN2018/094441 patent/WO2019007356A1/en not_active Ceased
- 2018-07-05 TW TW107123334A patent/TWI874298B/en active
-
2023
- 2023-05-01 US US18/310,020 patent/US20230404992A1/en not_active Abandoned
-
2024
- 2024-12-11 US US18/977,212 patent/US20250302818A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018295944B2 (en) | 2023-12-14 |
| TW201919633A (en) | 2019-06-01 |
| KR102785243B1 (en) | 2025-03-26 |
| CN110312513A (en) | 2019-10-08 |
| MX2020000029A (en) | 2020-08-06 |
| KR20200039677A (en) | 2020-04-16 |
| CN113491696A (en) | 2021-10-12 |
| TWI874298B (en) | 2025-03-01 |
| EP3648767A1 (en) | 2020-05-13 |
| CN110312513B (en) | 2022-07-08 |
| AU2018295944A1 (en) | 2020-02-20 |
| MY201703A (en) | 2024-03-13 |
| CA3068818A1 (en) | 2019-01-10 |
| US20230404992A1 (en) | 2023-12-21 |
| MA52924A (en) | 2021-04-28 |
| US20250302818A1 (en) | 2025-10-02 |
| US20210145819A1 (en) | 2021-05-20 |
| JP2020527134A (en) | 2020-09-03 |
| CN115300508A (en) | 2022-11-08 |
| JP7288404B2 (en) | 2023-06-07 |
| US11672792B2 (en) | 2023-06-13 |
| EP3648767A4 (en) | 2021-04-28 |
| WO2019007356A1 (en) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201911841PA (en) | Topical formulations comprising montelukast and combinations with mussel adhesive proteins | |
| EP3638700B8 (en) | Proteinaceous heterodimer and use thereof | |
| EP3647338A4 (en) | Macromolecular compound and light-emitting element using same | |
| ZA201802003B (en) | Dual function proteins and pharmaceutical composition comprising same | |
| EP3369795A4 (en) | ADHESIVE COMPOSITION AND THERMOFUSIBLE ADHESIVE | |
| EP3235830A4 (en) | Interleukin 15 protein complex and use thereof | |
| EP3271436A4 (en) | Hot melt adhesive composition and use thereof | |
| SG11201800578YA (en) | Mussel adhesive protein product and application thereof in inhibiting catarrh | |
| EP3255059A4 (en) | Antimicrobial peptide wy-21 and use thereof | |
| ZA201904704B (en) | Topical cyclosporine-containing formulations and uses thereof | |
| EP3290441A4 (en) | RGMa BINDING PROTEIN AND USE THEREOF | |
| EP3688036A4 (en) | Proteinaceous heterodimer and use thereof | |
| EP3226844A4 (en) | Proteins and protein conjugates with increased hydrophobicity | |
| EP3350276A4 (en) | An adhesive composition and an articlemanufactured therefrom | |
| IL268583A (en) | Topical formulations and methods | |
| EP3290489A4 (en) | Silicone adhesive composition and adhesive tape | |
| EP3489225A4 (en) | Vortioxetine analogue and use and preparation thereof | |
| EP3279209A4 (en) | Adhesive peptide and use therefor | |
| EP3554944B8 (en) | Insect elimination system and use thereof | |
| PL3173452T3 (en) | Adhesive strip and its use | |
| EP3604336A4 (en) | Anti-emap ii antibody and use thereof | |
| EP3325499A4 (en) | Novel peptide and use thereof | |
| EP3209697A4 (en) | Fn14-binding proteins and uses thereof | |
| HK40091844A (en) | Dual function proteins and pharmaceutical composition comprising same | |
| HK40097160A (en) | Anti-tim-3 antibodies and use thereof |